Categories

Volume 7 Issue 3 (March, 2019)

Original Articles

Effect of Tacrolimus Treatment on Blood Glucose level among Renal Transplanted Sudanese patients
Hiba Yasseir Mustafa Kamil, Abdelmula Mohamed Abdalla

Background:  Tacrolimus is immunosuppressive drug prevents graft rejection in renal transplanted patients. Recent researches suggested that tacrolimus might have side effect on renal function, lipid profile, and blood glucose level. Objective: To assess the effect of tacrolimus treatment on blood glucose levels in renal transplanted Sudanese patients. Materials and Method: Case control hospital base study was performed in Khartoum state at Sudanese Association specialized Hospital (Renal Transplant Center), during the period from Augusts to November 2018. 50 blood samples were collected from renal transplanted patients treated with tacrolimus. In addition to other 50 sample from healthy individual sex and age matched as control. Trough level of tacrolimus was measured by Cobas 411, fasting blood glucose measured by Cobas Integra 400 plus, and HbA1c was measured by mispa i2.  Results: The levels of FBG and HbA1C were significantly increased in the test group when compared with control group (141.48±57.73 mg/dl versus 88.53±8.041 mg/dl, p = 0.000 and 7.47±1.61% versus 4.39±0.57%, p = 0.000) respectively. Across gender the study observed that FBG level is significantly increased in female patients when compared to male patients in the study group (165.00±73.97mg/dl versus 128.25±42.02 mg/dl, p = 0.029). In contrast HbA1c level was insignificantly increased in female patients when compared to male patients in the study group (7.84±1.89% versus 7.26±1.43 %, p = 0.227). Also the study demonstrated significant positive correlation of both FBG and HA1C levels with tacrolimus dose (R=0.413, P=0.003 and R=0.284, P=0.046) respectively in the study group. Furthermore there is positive correlation between tacrolimus concentration and FBG (R=0.307,P=0.030),and duration of treatment with both  FBG and HA1c levels in the study group (R=0.455 P=0.001 and R=0.40, P 0.004) respectively. Also the study deduced positive correlation of CD Ratio with both FBG and HA1C levels in the study group (R=0.536, P=0.000, R=0.450, p = 0.001). Conclusion: the study bared that Calcineurin inhibitor tacrolimus is risk factor for hyperglycemia in renal-transplanted Sudanese patients.
Key words: Tacrolimus, immunosuppressive drug, Blood Glucose, Glycosylated hemoglobin (HbA1C), Renal Transplantation, Sudanese.

Received: 05 December  2018                          Accepted: 22 January 2019

Corresponding author: Abdelmula Mohamed Abdalla, Department of Clinical Chemistry, Faculty of Medical Laboratory Sciences, Alneelien University – Khartoum, Sudan

 This article may be cited as: Kamil HYM, Abdalla AM. Effect of Tacrolimus Treatment on Blood Glucose level among Renal Transplanted Sudanese patients. J Adv Med Dent Scie Res 2019;7(3):11-15

 
Html View | Download PDF | Current Issue


 
This work is licensed under a Creative Commons Attribution 3.0 License.  
?>